See more : Daitron Co., Ltd. (7609.T) Income Statement Analysis – Financial Results
Complete financial analysis of PaxMedica, Inc. Common Stock (PXMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PaxMedica, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kingwaytek Technology Co., Ltd. (6516.TWO) Income Statement Analysis – Financial Results
- The Toronto-Dominion Bank NCUM 5Y PFD SR18 (TD-PFJ.TO) Income Statement Analysis – Financial Results
- Industria de Diseño Textil, S.A. (IDEXY) Income Statement Analysis – Financial Results
- Lohakit Metal Public Company Limited (LHK.BK) Income Statement Analysis – Financial Results
- Rise Gold Corp. (RYES) Income Statement Analysis – Financial Results
PaxMedica, Inc. Common Stock (PXMD)
About PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.91M | 1.79M | 2.22M | 936.78K | 484.11K |
| General & Administrative | 12.23B | 8.82M | 4.97M | 4.63M | 114.50K |
| Selling & Marketing | -12.22B | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.23M | 8.82M | 4.97M | 4.63M | 114.50K |
| Other Expenses | 0.00 | -5.51M | 173.35K | -53.54K | 0.00 |
| Operating Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Cost & Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.17K | 5.24K | 2.81M | 609.46K | 0.00 |
| Depreciation & Amortization | 167.90K | -5.90M | 173.35K | -53.54K | 171.86K |
| EBITDA | -16.15M | -10.60M | -7.20M | -5.62M | -598.61K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.15M | -10.60M | -7.20M | -5.57M | -598.61K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.14M | -4.20M | -3.03M | -2.26M | 0.00 |
| Income Before Tax | -18.29M | -14.80M | -10.23M | -7.83M | -598.61K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -167.90K | 4.19M | 2.81M | 663.00K | -171.86K |
| Net Income | -18.29M | -14.80M | -13.03M | -8.49M | -598.61K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| EPS Diluted | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| Weighted Avg Shares Out | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
| Weighted Avg Shares Out (Dil) | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
PaxMedica Secures Immediate Exercise of Warrants
TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to...
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant...
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) ( OTC:PXMD ), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice...
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request...
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of...
Choosing Unknown Penny Stocks, 3 Top Tips
Penny stocks represent an exciting opportunity for investors looking to expand their portfolios with potentially lucrative, yet cost-effective options. Typically trading below five dollars per share, these stocks offer a gateway into investing with a smaller upfront financial commitment.
Why is PaxMedica (PXMD) stock surging today?
PaxMedica (NASDAQ: PXMD) has surged by 92.7% so far on Friday, reflecting the market's positive reaction to the company's announcement of significant progress in its drug development efforts.
Why is PaxMedica (PXMD) stock surging today?
PaxMedica (NASDAQ: PXMD) has surged by 92.7% so far on Friday, reflecting the market's positive reaction to the company's announcement of significant progress in its drug development efforts.
Why Is PaxMedica (PXMD) Stock Up 93% Today?
PaxMedica (NASDAQ: PXMD ) stock is rocketing higher on Friday after the clinical-stage biopharmaceutical company reached a key milestone in drug development. The big news here is the company securing three pivotal registration/validation batches of PAX-101.
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of...
Source: https://incomestatements.info
Category: Stock Reports